Periorbital Hyperpigmentation: Review of Etiology, Medical Evaluation, and Aesthetic Treatment

21. Roh MR, Chung KY. Infraorbital dark circles: definition, causes and treatment options. Dermatol Surg. 2009;35(8) 1163-1171.
22. Haddock NT, Saadeh PB, Boutros S, Thorne CH. The tear trough and lid/cheek junction:anatomy and implications for surgical correction. Plastic Reconstr Surg. 2009;123(4): 1332-1340.
23. Espinoza GM, Holds JB. Evaluation and treatment of the tear trough deformity in lower blepharoplasty. Semin Plast Surg. 2007 February; 21(1): 57–64.
24. Bickers DR, Athar M. Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol. 126:2565-75 2006.
25. Watanabe S, Nakai K, Ohnishi T. Condition known as “dark rings under the eyes” in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser. Dermatol Surg. 2006; 32:785–9.
26. Graziosi AC, Quaresma MR, Michalany NS, Ferreira LM.Cutaneous idiopathic hyperchromia of the orbital region (CIHOR): a histopathological study. Aesthetic Plast Surg. 2013 Apr;37(2):434-8. doi: 10.1007/s00266-012-0048-2.
27. Kolde G, Schmollack KP, Sterry W. Periorbital hyperpigmentation. Bilateral nevus of Ota. Hautarzt. 2001 May; 52(5):460-3.
28. Ing EB, Buncic JR, Weiser BA et al. Periorbital hyperpigmentation and erythema dyschromicum perstans. Can J Ophthalmol. 1992 Dec;27(7):353-5.
29. Manaloto RM, Alster TS. Periorbital rejuvenation: a review of dermatologic treatments. Dermatol Surg. 1999;25:1–9.
30. Berson DS, Cohen JL, Rendon MI, Roberts WE, Starker I, Wang B. Clinical role and application of superficial chemical peels in today’s practice. J Drugs Dermatol. 2009 Sep;8(9):803-11.
31. Vavouli C, Katsambas A, Chemical peeling with trichloroacetic acid and lactic acid for infraorbital dark circles. J Cosmet Dermatol. 2013 Sep;12(3):204-9.
32. Roberts WE. The Roberts Skin Type Classification System. J Drugs Dermatol. 2008 May;7(5):452-6.
33. Roberts WE Skin type classification systems old and new. Dermatol Clin. 2009 Oct;27(4):529-33.
34. Trelles MA Sight lost after lower lid laser blepharoplasty. Ann Plast Surg. 2000 Dec;45(6):678-9.
35. Lee WW, Murdock J, Albini TA et al. Ocular damage secondary to intense pulse light therapy to the face. Ophthal Plast Reconstr Surg. 2011 Jul-Aug;27(4):263-5.
36. Momosawa A, Kurita M, Ozaki M, Miyamoto S, et al. Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians. Plast Reconstr Surg. 2008;121:282–8.
37. West TB, Alster TS. Improvement of infraorbital hyperpigmentation following carbon dioxide laser resurfacing. Dermatol Surg. 1998 Jun 24 (6) 615-6.
38. Tierney EP, Hanke CW. Review of the literature: Treatment of dyspigmentation with fractionated resurfacing. Dermatol Surg. 2010 Oct;36(10):1499-508.
39. Mansukiatri W, Fitzpatrick RE, Goldman MP treatment of Facial skin using combinations of Co2, Q-switched alexandrite, flash-pumped pulde dye, and Er:YAG lasers in the same treatment session. Dermatol Surg. 2000; 26: 114-20.
40. Moody MN, Landau JM, Goldberg LH, Friedman PM. Fractionated 1550-nm erbium-doped fiber laser for the treatment of periorbital hyperpigmentation. Dermatol Surg. 2012 Jan;38(1):139-42.
41. Manstein, D, Herron GS, Sink RK, Tanner et al. Fractional phothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med. 2004;34:426-38.
42. Sherling M, Friedman PM, Adrian R, Burns AJ et al. Consensus recommendations on the use of an erbium-doped 1,550 nm fractionated laser and its applications in dermatologic laser surgery. Dermatol Surg. 2010;36:461-9.
43. Ruiz- Esparza J. Noninvasive lower eyelid blepharoplasty: a new technique using nonablative radiofrequency on periorbital skin. Dermatol Surg. 2004 Feb;30(2 Pt 1):125-9.
44. Sukal SA, Geronemus RG. Thermage: the nonablative radiofrequency for rejuvenation. Clin Dermatol. 2008 Nov-Dec;26(6):602-7.
45. Carruthers J, Rzany B, Sattler G, Carruthers A. Anatomic guidelines for midface volumetric augmentation. Dermatol Surg. 2012;38:1223–33.
46. Sadick NS, Bosniak SL, Cantisano-Zilkha M, Glavas IP, Roy D. Definition of the tear trough and the tear trough rating scale. J Cosmet Dermatol. 2007;6:218–22.
47. Matarasso SL, Carruthers J, Jewell ML, Restylane Consensus Group. Consensus recommendation for soft-tissue augmentation with nonanimal stabilized hyaluronic acid (Restylane). Plast Reconstr Surg. 2006;117:3S-34S.
48. Sattler G. The tower technique and vertical supraperiosteal depot technique: Novel vertical injection techniques for volume-efficient subcutaneous tissue support and volumetric augmentation. J Drugs Dermatol. 2012;11:45-7.
49. Sharad J. Dermal fillers for the treatment of tear trough deformity: a review of anatomy, treatment techniques, and their outcomes. J Cutan Aesthet Surg. 2012;5(4): 229–238.
50. Rzany B, Becker-Wegerich P, Bachmann F, Erdmann R, Wollina U. Hyaluronidase in the correction of hyaluronic acid-based fillers: a review and a recommendation for use. J Cosmet Dermatol. 2009 Dec;8(4):317-23.
51. Ciuci PM, Obagi S. Rejuvenation of the periorbital complex with autologous fat transfer: current therapy. J Oral Maxillofac Surg. 2008 Aug;66(8):1686-93.
52. Tonnard PL, Verpaele AM, Zeltzer AA. Augmentation blepharoplasty: a review of 500 consecutive patients. Aesthet Surg J. 2013 Mar;33(3):341-52.
53. SBruce Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months. J Drugs Dermatol. 2013 Mar;12(3):S27-31
54. Fabi SG, Goldman MP. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging. J Drugs Dermatol. 2013 Mar;12(3):S32-7.

AUTHOR CORRESPONDENCE